+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccine Raw Materials Market - Global Forecast 2025-2030- Product Image
mRNA Vaccine Raw Materials Market - Global Forecast 2025-2030- Product Image
Sale

mRNA Vaccine Raw Materials Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6145721
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global mRNA vaccine raw materials market underpins critical vaccine innovation, with supply chain agility, specialized components, and rapid response capabilities shaping strategic priorities. Organizations must navigate a complex ecosystem of suppliers, evolving regulations, and technical advancements to maintain a reliable supply of quality raw materials for mRNA vaccine manufacturing.

Market Snapshot

The mRNA vaccine raw materials market is experiencing sustained growth, driven by heightened demand for pandemic response solutions, regulatory shifts, and technology improvements in synthesis, delivery, and purification. As mRNA vaccine platforms expand, the reliance on specialized reagents such as lipids, enzymes, and solvents becomes more prominent, intensifying the focus on resilient supply chains and high-quality input sourcing. Systematic investment in domestic manufacturing and supplier diversification is reshaping procurement, while advancements in lipid nanoparticles and nucleotide triphosphate synthesis continue to raise the bar for efficiency and safety in vaccine development.

Scope & Segmentation

  • Material Types: Buffers (HEPES, phosphate buffer, Tris buffer), capping enzymes (Vaccinia capping enzyme), lipids (cholesterol, ionizable, PEGylated, structural), nucleotide triphosphates (ATP, CTP, GTP, UTP), purification resins (affinity, ion exchange), salt reagents (potassium chloride, sodium chloride), and solvents (ethanol, isopropanol).
  • Delivery Systems: Exosome-based carriers (engineered and natural), lipid nanoparticles (ionizable and PEGylated lipid particles), peptide carriers (cell penetrating, fusogenic), polymeric nanoparticles (chitosan, PLGA particles).
  • Process Stages: Capping, filling and finishing, formulation, purification, synthesis, each requiring precise raw material selection and handling protocols.
  • End Use: Applications in human vaccines and veterinary vaccines, each with tailored technical and regulatory requirements.
  • Applications: Infectious diseases (COVID-19, influenza) and oncology segments (hematologic, solid tumor vaccines) drive differentiated needs for formulation and component specifications.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, and others) offer distinct market dynamics, infrastructure maturity, and regulatory frameworks.
  • Leading Companies: Key suppliers include Thermo Fisher Scientific Inc., Merck KGaA, Evonik Industries AG, CordenPharma Holding GmbH, Avanti Polar Lipids, Inc., Azenta, Inc., Precision NanoSystems Inc., Polyplus-transfection SA, Polymun Scientific Immunbiologische Forschung GmbH, and Acuitas Therapeutics, Inc.

Key Takeaways

  • Innovations in lipid nanoparticle design and enzyme engineering are enhancing delivery efficiency and vaccine safety across global production environments.
  • Segmented demand for buffers, nucleotides, and specialized resins reflects unique process requirements from synthesis to final formulation for both human and veterinary applications.
  • Strategic supplier diversification and investments in domestic manufacturing are becoming vital for resilience amid evolving trade and tariff landscapes.
  • Regulatory flexibility enables adoption of novel suppliers but requires robust quality management and end-to-end supply chain transparency to safeguard compliance.
  • Geographical investment and expansion strategies help market leaders navigate regional infrastructure differences and logistics challenges in sourcing mRNA vaccine raw materials.
  • Sustainability pressures prompt exploration of greener reagents and synthesis methods, adding a new dimension to supplier and product selection.

Tariff Impact on the mRNA Vaccine Raw Materials Market

Recently implemented United States tariffs have increased import duties on essential inputs such as specialty lipids, purification resins, and nucleotide precursors. This is prompting procurement teams to renegotiate contracts, invest in domestic production, and forge partnerships with overseas suppliers in countries with more favorable trade conditions. Logistics providers are responding by introducing services to optimize cross-border shipments and lower landed costs, underscoring the need for adaptive sourcing and robust risk management to support R&D and production continuity.

Methodology & Data Sources

This report synthesizes primary research through detailed interviews with suppliers, logistics experts, and manufacturers, ensuring first-hand industry visibility. Secondary sources include peer-reviewed publications, regulatory documents, patents, and publicly reported financials. Data triangulation and subject matter expert review underpin the precision and reliability of the findings.

Why This Report Matters

  • Informs decisions on supplier qualification, material innovation, and risk mitigation across the mRNA vaccine raw materials supply chain.
  • Supports strategic planning for procurement, manufacturing, and regulatory engagement, with perspectives on both domestic and global trends.
  • Helps stakeholders optimize sourcing, ensure quality standards, and anticipate material needs as vaccine formulations and delivery platforms evolve.

Conclusion

This comprehensive analysis provides senior decision-makers with essential market intelligence to address the evolving demands of mRNA vaccine raw materials. By leveraging segmentation insights and understanding shifting trade policies, organizations can strengthen their strategies for continued leadership in vaccine manufacturing.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Optimization of enzymatic mRNA cap analog production to enhance vaccine stability
5.2. Integration of recombinant lipid nanoparticle purification techniques to reduce impurities
5.3. Scale-up strategies for in vitro transcription reagents to meet global mRNA vaccine demand
5.4. Development of sustainable raw material sourcing to minimize supply chain disruptions in mRNA production
5.5. Evaluation of novel ionizable lipids for improved endosomal escape in mRNA vaccine delivery systems
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA Vaccine Raw Materials Market, by Material Type
8.1. Introduction
8.2. Buffers
8.2.1. Hepes
8.2.2. Phosphate Buffer
8.2.3. Tris Buffer
8.3. Capping Enzymes
8.3.1. Vaccinia Capping Enzyme
8.4. Lipids
8.4.1. Cholesterol
8.4.2. Ionizable Lipids
8.4.3. Pegylated Lipids
8.4.4. Structural Lipids
8.5. Nucleotide Triphosphates
8.5.1. ATP
8.5.2. CTP
8.5.3. GTP
8.5.4. UTP
8.6. Purification Resins
8.6.1. Affinity
8.6.2. Ion Exchange
8.7. Salt Reagents
8.7.1. Potassium Chloride
8.7.2. Sodium Chloride
8.8. Solvents
8.8.1. Ethanol
8.8.2. Isopropanol
9. mRNA Vaccine Raw Materials Market, by Delivery System
9.1. Introduction
9.2. Exosome Based
9.2.1. Engineered Exosomes
9.2.2. Natural Exosomes
9.3. Lipid Nanoparticles
9.3.1. Ionizable Lipid Particles
9.3.2. Pegylated Lipid Particles
9.4. Peptide Based
9.4.1. Cell Penetrating Peptides
9.4.2. Fusogenic Peptides
9.5. Polymeric Nanoparticles
9.5.1. Chitosan Particles
9.5.2. PLGA Particles
10. mRNA Vaccine Raw Materials Market, by Process Stage
10.1. Introduction
10.2. Capping
10.3. Filling And Finishing
10.4. Formulation
10.5. Purification
10.6. Synthesis
11. mRNA Vaccine Raw Materials Market, by End Use
11.1. Introduction
11.2. Human Vaccines
11.3. Veterinary Vaccines
12. mRNA Vaccine Raw Materials Market, by Application
12.1. Introduction
12.2. Infectious Diseases
12.2.1. COVID-19 Vaccines
12.2.2. Influenza Vaccines
12.3. Oncology
12.3.1. Hematologic Vaccine
12.3.2. Solid Tumor Vaccines
13. Americas mRNA Vaccine Raw Materials Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa mRNA Vaccine Raw Materials Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific mRNA Vaccine Raw Materials Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Evonik Industries AG
16.3.4. CordenPharma Holding GmbH
16.3.5. Avanti Polar Lipids, Inc.
16.3.6. Azenta, Inc.
16.3.7. Precision NanoSystems Inc.
16.3.8. Polyplus-transfection SA
16.3.9. Polymun Scientific Immunbiologische Forschung GmbH
16.3.10. Acuitas Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MRNA VACCINE RAW MATERIALS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MRNA VACCINE RAW MATERIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MRNA VACCINE RAW MATERIALS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHAI
FIGURE 26. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHSTATISTICS
FIGURE 27. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHCONTACTS
FIGURE 28. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MRNA VACCINE RAW MATERIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PHOSPHATE BUFFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PHOSPHATE BUFFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY TRIS BUFFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY TRIS BUFFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VACCINIA CAPPING ENZYME, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VACCINIA CAPPING ENZYME, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHOLESTEROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHOLESTEROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STRUCTURAL LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STRUCTURAL LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ATP, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ATP, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY GTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY GTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY UTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY UTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY AFFINITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY AFFINITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ION EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ION EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POTASSIUM CHLORIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POTASSIUM CHLORIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SODIUM CHLORIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SODIUM CHLORIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ETHANOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ETHANOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ISOPROPANOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ISOPROPANOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ENGINEERED EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ENGINEERED EXOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NATURAL EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NATURAL EXOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPID PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPID PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPID PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPID PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FUSOGENIC PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FUSOGENIC PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHITOSAN PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHITOSAN PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PLGA PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PLGA PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FILLING AND FINISHING, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FILLING AND FINISHING, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEMATOLOGIC VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEMATOLOGIC VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLID TUMOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLID TUMOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 221. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 222. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 223. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 224. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 225. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 226. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 227. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 228. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 229. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 230. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 231. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 232. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 233. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 234. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 235. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 236. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 237. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 238. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 239. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 240. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 241. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 242. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 243. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 244. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 245. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 246. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 247. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 248. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 249. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 250. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 251. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 254. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 255. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 256. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 257. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 258. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 259. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 260. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 261. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 262. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 263. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 266. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 267. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 269. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 274. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 275. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 276. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 277. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 278. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 279. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 280. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 281. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 282. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 283. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 284. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 285. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 286. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 287. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 290. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 291. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 292. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL MRNA VACCINE RAW MATE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this mRNA Vaccine Raw Materials market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Evonik Industries AG
  • CordenPharma Holding GmbH
  • Avanti Polar Lipids, Inc.
  • Azenta, Inc.
  • Precision NanoSystems Inc.
  • Polyplus-transfection SA
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Acuitas Therapeutics, Inc.

Related Topics

Related Reports

mRNA Vaccine Drugs Development Services Market - Global Forecast 2025-2030 - Product Image

mRNA Vaccine Drugs Development Services Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
mRNA Vaccines Market - Global Forecast 2025-2030 - Product Image

mRNA Vaccines Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
mRNA Vaccines and Therapeutics Market Report by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2025-2033 - Product Image

mRNA Vaccines and Therapeutics Market Report by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions - Product Image

mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions

  • Report
  • 343 Pages
  • Global
From
mRNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

mRNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.